Nykode Therapeutics AS

OB:NYKD Stock Report

Market Cap: NOK 943.1m

Nykode Therapeutics Valuation

Is NYKD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NYKD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NYKD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NYKD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NYKD?

Key metric: As NYKD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NYKD. This is calculated by dividing NYKD's market cap by their current revenue.
What is NYKD's PS Ratio?
PS Ratio19x
SalesUS$4.37m
Market CapUS$83.25m

Price to Sales Ratio vs Peers

How does NYKD's PS Ratio compare to its peers?

The above table shows the PS ratio for NYKD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.8x
AZT ArcticZymes Technologies
6.2x14.2%NOK 687.4m
HBC Hofseth BioCare
2.5xn/aNOK 631.0m
LYTIX Lytix Biopharma
26.3x137.9%NOK 282.8m
PCIB PCI Biotech Holding
8.2xn/aNOK 49.3m
NYKD Nykode Therapeutics
19x21.8%NOK 943.1m

Price-To-Sales vs Peers: NYKD is expensive based on its Price-To-Sales Ratio (19x) compared to the peer average (10.8x).

Price to Sales Ratio vs Industry

How does NYKD's PS Ratio compare vs other companies in the European Biotechs Industry?

41 CompaniesPrice / SalesEstimated GrowthMarket Cap
NYKD 19.0xIndustry Avg. 8.1xNo. of Companies41PS0816243240+
41 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NYKD is expensive based on its Price-To-Sales Ratio (19x) compared to the European Biotechs industry average (8.2x).

Price to Sales Ratio vs Fair Ratio

What is NYKD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NYKD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio19x
Fair PS Ratio4.7x

Price-To-Sales vs Fair Ratio: NYKD is expensive based on its Price-To-Sales Ratio (19x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NYKD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 2.89
NOK 11.50
+298.2%
72.9%NOK 25.00NOK 4.00n/a4
Dec ’25NOK 2.68
NOK 17.75
+562.3%
106.3%NOK 50.00NOK 4.00n/a4
Nov ’25NOK 4.65
NOK 25.75
+453.3%
56.0%NOK 50.00NOK 12.00n/a4
Oct ’25NOK 4.37
NOK 25.75
+489.0%
56.0%NOK 50.00NOK 12.00n/a4
Sep ’25NOK 6.44
NOK 29.13
+352.3%
43.4%NOK 50.00NOK 17.50n/a4
Aug ’25NOK 14.85
NOK 36.63
+146.6%
54.4%NOK 70.00NOK 17.50n/a4
Jul ’25NOK 14.88
NOK 43.00
+189.0%
44.5%NOK 70.00NOK 28.00n/a3
Jun ’25NOK 15.78
NOK 43.00
+172.5%
44.5%NOK 70.00NOK 28.00n/a3
May ’25NOK 13.37
NOK 43.00
+221.6%
44.5%NOK 70.00NOK 28.00n/a3
Apr ’25NOK 14.99
NOK 43.00
+186.9%
44.5%NOK 70.00NOK 28.00n/a3
Mar ’25NOK 16.99
NOK 66.67
+292.4%
45.5%NOK 102.00NOK 28.00n/a3
Feb ’25NOK 17.88
NOK 66.67
+272.9%
45.5%NOK 102.00NOK 28.00n/a3
Jan ’25NOK 21.40
NOK 67.00
+213.1%
44.6%NOK 102.00NOK 29.00n/a3
Dec ’24NOK 17.50
NOK 67.00
+282.9%
44.6%NOK 102.00NOK 29.00NOK 2.683
Nov ’24NOK 17.06
NOK 67.00
+292.7%
44.6%NOK 102.00NOK 29.00NOK 4.653
Oct ’24NOK 23.70
NOK 67.00
+182.7%
44.6%NOK 102.00NOK 29.00NOK 4.373
Sep ’24NOK 29.06
NOK 67.00
+130.6%
44.6%NOK 102.00NOK 29.00NOK 6.443
Aug ’24NOK 29.12
NOK 65.50
+124.9%
55.7%NOK 102.00NOK 29.00NOK 14.852
Jul ’24NOK 26.20
NOK 65.50
+150.0%
55.7%NOK 102.00NOK 29.00NOK 14.882
Jun ’24NOK 27.76
NOK 65.50
+136.0%
55.7%NOK 102.00NOK 29.00NOK 15.782
May ’24NOK 25.70
NOK 65.50
+154.9%
55.7%NOK 102.00NOK 29.00NOK 13.372
Apr ’24NOK 21.82
NOK 65.50
+200.2%
55.7%NOK 102.00NOK 29.00NOK 14.992

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nykode Therapeutics AS is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Viktor SundbergABG Sundal Collier Sponsored
Geir HolomDNB Markets
Patrick TrucchioH.C. Wainwright & Co.